Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 2569 results for methods

  1. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  2. Shared decision making (NG197)

    This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.

  3. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  4. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

  5. The PediGuard for placing pedicle screws in spinal surgery (MIB26)

    NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery

  6. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy.

  7. Chemical sympathectomy for managing critical limb ischaemic pain:- What is the clinical and cost effectiveness of chemical sympathectomy in comparison with other methods of pain control for managing critical limb ischaemic pain?

    and cost effectiveness of chemical sympathectomy in comparison with other methods of pain control for managing critical limb ischaemic...

  8. User guide for the cost comparison company evidence submission template (PMG32)

    This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented

  9. Mini/micro screw implantation for orthodontic anchorage (HTG152)

    Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.

  10. Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects, and engaging patients in prescribing decisions?

    Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong...

  11. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

  12. Promoting a shift to zero- and low-emission travel:- What methods are effective and cost effective at promoting a shift to zero- and low-emission modes of travel, including active travel?

    Question Promoting a shift to zero- and low-emission travel:- What methods are effective and cost effective at promoting a shift to...

  13. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

  14. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development Reference number: GID-TA10867 Expected publication date: TBC

  15. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC